Investigational drug · Phase 2
ECC0509
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metabolic Dysfunction-associated Steatohepatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ECC0509"
First trial start
2025
Dec 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ECC0509", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metabolic Dysfunction-associated Steatohepatitis
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ECC0509" as an intervention, largest first.
EccogeneIndustry
NCT07288138 · 160 participants (planned) · Start Dec 15, 2025 · Primary completion Sep 15, 2027
Drug: Placebo; ECC4703 and 2 more · For: Metabolic Dysfunction-associated Steatohepatitis
Sites: Chandler, Arizona; Peoria, Arizona; Tucson, Arizona · 70 sites in all
EccogeneIndustry
NCT05012423 · 89 participants · Start Jul 26, 2021 · Primary completion Jul 22, 2023
Drug: Placebo; ECC0509 and 2 more · For: Nonalcoholic Steatohepatitis; Osteoarthritis
Sites: Adelaide, Australia
- DDI Study of ECC0509 With Metformin, Midazolam, and CaffeineNot yet recruiting
EccogeneIndustry
NCT07873229 · 40 participants (planned) · Start Nov 2026 · Primary completion Mar 2027
Drug: ECC0509; Metformin and 2 more · For: Steatohepatitis, Nonalcoholic; Osteo Arthritis
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metabolic Dysfunction-associated Steatohepatitis
- EfimosferminBOS-580Phase 37 trials
GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic
- ALN-CIDEBPhase 34 trials
Regeneron · Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD
- ARO-INHBEPhase 22 trials
Arrowhead Pharmaceuticals · Metabolic Dysfunction-Associated Steatohepatitis, Obesity
- ECC4703Phase 22 trials
Eccogene · Adult Obesity, Weight Management, Metabolic Dysfunction-associated Steatohepatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.